Mitchell Chan Net Worth

Mitchell Chan biography

Mitchell Chan serves as Chief Financial Officer of the Company. Mr. Chan joined us in September 2018 as our Vice President, Head of Finance and Corporate Strategy. Mr. Chan is responsible for leading our corporate financing, financial operations, accounting, tax, treasury, investor relations, public relations and developing corporate strategy. Since September 2015 until August 2018, Mr. Chan was the Director of Investor Relations for AstraZeneca, North America. Prior to AstraZeneca, Mr. Chan served in various roles of increasing responsibility at Genentech-Roche from June 2010 to August 2015, most recently as Sr. Finance Manager.

What is the salary of Mitchell Chan?

As the Chief Financial Officer of Viela Bio, the total compensation of Mitchell Chan at Viela Bio is $892,361. There are 2 executives at Viela Bio getting paid more, with Zhengbin Yao having the highest compensation of $2,747,550.

How old is Mitchell Chan?

Mitchell Chan is 39, he's been the Chief Financial Officer of Viela Bio since 2019. There are 10 older and 1 younger executives at Viela Bio. The oldest executive at Viela Bio, Inc. is Chris Nolet, 63, who is the Independent Director.

What's Mitchell Chan's mailing address?

Mitchell's mailing address filed with the SEC is C/O VIELA BIO, INC.,, ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG, MD, 20878.

Insiders trading at Viela Bio

Over the last 5 years, insiders at Viela Bio have traded over $58,712,400 worth of Viela Bio stock and bought 1,261,091 units worth $24,062,867 . The most active insiders traders include Andreas Wicki, Xiaomeng Tong и Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of $6,348. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth $5,680.

What does Viela Bio do?

Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.

Viela Bio executives and stock owners

Viela Bio executives and other stock owners filed with the SEC include:

• Zhengbin Yao,
  Chairman of the Board, President, Chief Executive Officer
• Jorn Drappa,
  Chief Medical Officer, Head of Research and Development
• Mitchell Chan,
  Chief Financial Officer
• Aaron Ren,
  Vice President - Head of Business Development and Operations
• Chris Nolet,
  Independent Director
• Edward Hu,
  Independent Director
• Yanling Cao,
  Director
• Chad Rubin,
  IR Contact Officer
• Andreas Wicki,
  Independent Director
• Tyrell Rivers,
  Independent Director
• Rachelle Jacques,
  Independent Director
• Sean Tong,
  Director
• Jim Kastenmayer,
  General Counsel, Secretary
• William Ragatz,
  Vice President - Head of Commercial
• Xiaomeng Tong,
  Director
• Plc Astra Zeneca Uk Ltd Ast...,
  
• Meadow Ltd Boundless,
  10% owner
• James Paul Kastenmayer,
  General Counsel
• Meadow Ltd Boyu Capital Fun...,